News Releases

Date Title
08/12/2013 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013
07/25/2013 Summary ToggleEnanta Pharmaceuticals, Inc. [ENTA] Celebrates Their Recent IPO and Recognizes World Hepatitis Day by Ringing The NASDAQ Stock Market Opening Bell
07/01/2013 Summary ToggleEnanta Pharmaceuticals Added to the Russell 3000® and Russell 2000® Indexes
07/01/2013 Summary ToggleEnanta Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference
06/14/2013 Summary ToggleEnanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference
05/28/2013 Summary ToggleEnanta Pharmaceuticals to Present at Upcoming Investor Conferences
05/08/2013 Summary ToggleEnanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013
05/06/2013 Summary ToggleBreakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450
04/23/2013 Summary ToggleEnanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
03/26/2013 Summary ToggleEnanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option